Table 1.
Beneficial effect | Biomarker | Outcome | Effective compound | P Value significance |
---|---|---|---|---|
Immune enhancement | Monocyte | Increase | AFO-202 | <0.05 |
Eosinophils | AFO-202 | <0.05 | ||
CRP | AFO-202 | |||
IL-7 | AFO-202 | <0.05 | ||
IL8 | AFO-202 | <0.05 | ||
Immmunomodulation | IgA | Increase | AFO-202 +N-163 | <0.01 |
IL-2 | AFO-202 +N-163 | <0.05 | ||
LCR | AFO-202 +N-163 | |||
LeCR | AFO-202 +N-163 | |||
NLR | Decrease | AFO-202 +N-163 | <0.05 | |
Metabolic regulation | HbA1c | Decrease | AFO-202 | <0.05 |
Glycated Albumin | AFO-202 | <0.05 | ||
T-Cho | AFO-202 +N-163 | <0.05 | ||
LDL-Cho | AFO-202 +N-163 | <0.01 | ||
Coagulopathy prevention | D-Dimer | Decrease | AFO-202 | <0.05 |
Ferritin | AFO-202 +N-163 | |||
Fibrinogen | AFO-202 +N-163 | |||
Galectin-3 | AFO-202 +N-163 | |||
CD11b | Increase | AFO-202 +N-163 |
Abbreviations: CRP- C-reactive protein; IL-Interleukin; Ig-Immunoglobin; LCR-Lymphocyte to C-reactive protein ratio; NLR- Neutrophil to Lymphocyte ratio; LeCR-Leukocyte to C-reactive protein ratio; LDL-Low density lipoprotein